2 weeks Ago By Defense World Staff
Bokf Na increased its holdings in shares of GSK plc ( NYSE:GSK – Free Report ) by 20.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,389 shares of the pharmaceutical company’s stock after purchasing an additional 1,787 shares during the period.
Bokf Na’s holdings in GSK were worth $400,000 at the end of the most recent quarter. Several other institutional investors have also modified their holdings of the business. American Century Companies Inc.
lifted its holdings in shares of GSK by 42.2% during the 2nd quarter. American Century Companies Inc.
now owns 544,079 shares of the pharmaceutical company’s stock valued at $20,947,000 after purchasing an additional 161,448 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of GSK during the 2nd quarter valued at about $1,183,000. Provident Investment Management Inc.
lifted its holdings in shares of GSK by 171.0% during the 2nd quarter. Provident Investment Management Inc.
now owns 17,670 shares of the pharmaceutical company’s stock valued at $680,000 after purchasing an additional 11,150 shares in the last quarter. Choreo LLC lifted its holdings in shares of GSK by 759.4% during the 2nd quarter.
Choreo LLC now owns 52,157 shares of the pharmaceutical company’s stock valued at $2,002,000 after purchasing an additional 46,088 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in GSK in the 2nd quarter valued at approximately $37,000. Institutional investors own 15.
74% of the company’s stock. Analysts Set New Price Targets A number of equities research analysts recently issued reports on the company. Berenberg Bank raised GSK to a “strong-buy” rating in a research report on Thursday, June 20th.
Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Argus raised GSK to a “strong-buy” rating in a research report on Wednesday, August 7th.
Finally, Jefferies Financial Group lifted their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd.
Four analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, GSK currently has an average rating of “Buy” and an average price target of $50.
00. GSK Stock Up 1.3 % NYSE:GSK opened at $43.
55 on Tuesday. The firm has a market capitalization of $90.26 billion, a price-to-earnings ratio of 15.
78, a price-to-earnings-growth ratio of 1.41 and a beta of 0.66.
GSK plc has a twelve month low of $33.67 and a twelve month high of $45.92.
The stock’s 50 day moving average price is $41.14 and its two-hundred day moving average price is $41.70.
The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.
99. GSK ( NYSE:GSK – Get Free Report ) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.
09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09.
The business had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion.
GSK had a return on equity of 51.48% and a net margin of 12.87%.
Equities research analysts expect that GSK plc will post 4.15 earnings per share for the current fiscal year. GSK Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th.
Investors of record on Friday, August 16th will be issued a dividend of $0.3843 per share. The ex-dividend date is Friday, August 16th.
This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.
54 dividend on an annualized basis and a dividend yield of 3.53%. GSK’s payout ratio is presently 54.
71%. GSK Profile ( Free Report ) GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Further Reading Five stocks we like better than GSK The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible Natural Gas Prices Continue To Rally, These Stocks Should Benefit Roblox’s Growth Beyond Kids: Stock Set for Major Moves The 3 Best Blue-Chip Stocks to Buy Now 5 Oversold Stocks to Buy Right Now Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter ..
